News Image

NASDAQ:EXEL is an undervalued gem with solid fundamentals.

By Mill Chart

Last update: Mar 29, 2024

Our stock screener has spotted EXELIXIS INC (NASDAQ:EXEL) as an undervalued stock with solid fundamentals. NASDAQ:EXEL shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.

Understanding NASDAQ:EXEL's Valuation

ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:EXEL, the assigned 7 reflects its valuation:

  • 95.41% of the companies in the same industry are more expensive than EXEL, based on the Price/Earnings ratio.
  • Based on the Price/Forward Earnings ratio, EXEL is valued cheaper than 96.94% of the companies in the same industry.
  • Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaply inside the industry as 94.90% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, EXEL is valued cheaper than 96.60% of the companies in the same industry.
  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of EXEL may justify a higher PE ratio.
  • A more expensive valuation may be justified as EXEL's earnings are expected to grow with 45.50% in the coming years.

A Closer Look at Profitability for NASDAQ:EXEL

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:EXEL has earned a 7 out of 10:

  • The Return On Assets of EXEL (7.06%) is better than 96.60% of its industry peers.
  • The Return On Equity of EXEL (9.18%) is better than 95.92% of its industry peers.
  • EXEL has a better Return On Invested Capital (5.31%) than 95.58% of its industry peers.
  • Looking at the Profit Margin, with a value of 11.35%, EXEL belongs to the top of the industry, outperforming 96.26% of the companies in the same industry.
  • EXEL has a better Operating Margin (9.34%) than 95.58% of its industry peers.
  • With an excellent Gross Margin value of 96.04%, EXEL belongs to the best of the industry, outperforming 96.43% of the companies in the same industry.

A Closer Look at Health for NASDAQ:EXEL

ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NASDAQ:EXEL, the assigned 7 reflects its health status:

  • EXEL has an Altman-Z score of 7.47. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
  • EXEL's Altman-Z score of 7.47 is amongst the best of the industry. EXEL outperforms 81.80% of its industry peers.
  • EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • A Current Ratio of 3.34 indicates that EXEL has no problem at all paying its short term obligations.
  • EXEL has a Quick Ratio of 3.30. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.

Exploring NASDAQ:EXEL's Growth

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:EXEL has received a 5 out of 10:

  • The Earnings Per Share has grown by an nice 12.28% over the past year.
  • Looking at the last year, EXEL shows a quite strong growth in Revenue. The Revenue has grown by 13.60% in the last year.
  • Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 16.47% on average per year.
  • The Earnings Per Share is expected to grow by 30.94% on average over the next years. This is a very strong growth
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Our Decent Value screener lists more Decent Value stocks and is updated daily.

Our latest full fundamental report of EXEL contains the most current fundamental analsysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

EXELIXIS INC

NASDAQ:EXEL (4/25/2024, 7:00:01 PM)

After market: 23.53 0 (0%)

23.53

-0.18 (-0.76%)

EXEL News

News Image2 days ago - ChartmillTechnical Signals Point to a Possible Breakout for EXELIXIS INC.

EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

News Image2 days ago - ChartmillNASDAQ:EXEL is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.

News Image9 days ago - Exelixis, Inc.Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
News Imagea month ago - InvestorPlace3 Biotech Stocks to Buy on the Dip: March 2024

Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.

News Imagea month ago - The Motley Fool4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.

News Image2 months ago - The Motley Fool2 Biotech Stocks to Buy Hand Over Fist in March

These stocks are worth buying in most months of the year.

News Image2 months ago - InvestorPlace3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success

With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.

News Image2 months ago - The Motley Fool4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.

News Image2 months ago - Exelixis, Inc.Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
News Image2 months ago - Market News VideoFriday 2/23 Insider Buying Report: EXEL, HPP
News Image2 months ago - The Motley Fool2 Stocks Under $30 to Buy and Hold

You don't need to be a millionaire to get started. Investing on a budget can work, too.

News Image2 months ago - FinancialNewsMediaAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

EXEL Links
Follow us for more